Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report.
Posts Tagged ‘NASDAQ:ALKS’
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript May 5, 2026Alkermes plc beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.57.
10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More
Ten stocks soared by double digits on Tuesday, outperforming Wall Street, as investors took heart from a flurry of corporate and industry developments, including acquisition deals...
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript February 25, 2026Alkermes plc misses on earnings expectations.
Jim Cramer Recently Looked at These 25 Stocks
Jim Cramer, the host of Mad Money, on Friday commented on the ongoing chip shortages and also discussed Micron’s decision to break ground on a domestic chip manufacturing facility...
Why Analysts are Rating Alkermes (ALKS) a Buy
Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50.
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment
Alkermes Plc (NASDAQ:ALKS) is one of the best breakout stocks to invest in.
10 Best Breakout Stocks to Invest In
In this article, we will take a look at the 10 Best Breakout Stocks to Invest In.
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call Transcript October 28, 2025Alkermes plc beats earnings expectations. Reported EPS is $0.4911, expectations were $0.42.
HC Wainwright Affirms Alkermes (ALKS) ‘Neutral’ Rating on Vibrance-1 Phase 2 Study
Alkermes (NASDAQ:ALKS) is one of the best beginner stocks to buy, according to analysts.
12 Best Beginner Stocks to Buy According to Analysts
In this article, we discuss the 12 Best Beginner Stocks to Buy According to Analysts.
Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Alkermes plc is one of them.
13 Best Psychedelic Stocks to Invest in Now
In this article, we will be taking a look at the 13 Best Psychedelic Stocks to Invest in Now.
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript July 29, 2025Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations were $0.41.
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most undervalued stocks.
10 Most Undervalued Pharma Stocks to Buy Now
In this article, we will be taking a look at the 10 Most Undervalued Pharma Stocks to Buy Now. Pharmaceutical manufacturing in the U.S.
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating
Alkermes plc (NASDAQ:ALKS) is one of the high-margin pharma stocks to buy now.
10 Best High-Margin Pharma Stocks to Buy Now
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential
In this article, we discuss Billionaire Jim Simons' RenTech's 10 Small-Cap Stock Picks with Huge Upside Potential.
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript May 1, 2025Alkermes plc misses on earnings expectations. Reported EPS is $0.13 EPS, expectations were $0.28.
10 Best Healthcare Stocks For Long-Term Investment
In this article, we will be taking a look at the 10 best healthcare stocks for long-term investment.
12 Best Psychedelic Stocks to Buy in 2025
In this article, we will be taking a look at the 12 best psychedelic stocks to buy in 2025.
Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Call Transcript February 12, 2025Alkermes plc beats earnings expectations. Reported EPS is $1.05, expectations were $0.81.
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript October 24, 2024Alkermes plc misses on earnings expectations. Reported EPS is $0.553 EPS, expectations were $0.78.
10 Most Undervalued Quality Stocks To Buy According To Analysts
In this article, we will talk about the 10 most undervalued quality stocks to buy according to analysts.
Alkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Call Transcript July 24, 2024Alkermes plc misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.73.
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024 Alkermes plc misses on earnings expectations. Reported EPS is $0.22 EPS, expectations were $0.46.
12 Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates
In this piece, we will take a look at the 12 best growth stocks to buy according to billionaire Ray Dalio's Bridgewater Associates.
Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks
In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio.
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript October 25, 2023 Alkermes plc beats earnings expectations. Reported EPS is $0.64, expectations were $0.44.
Alkermes plc (NASDAQ:ALKS) Q2 2023 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q2 2023 Earnings Call Transcript July 26, 2023 Alkermes plc misses on earnings expectations. Reported EPS is $0.55 EPS, expectations were $0.56.
Alkermes plc (NASDAQ:ALKS) Q1 2023 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q1 2023 Earnings Call Transcript April 26, 2023 Alkermes plc beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01.
Alkermes plc (NASDAQ:ALKS) Q4 2022 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Greetings and welcome to the Alkermes Fourth Quarter 2022 Financial Results Conference ...
10 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Brandon Haley’s Holocene Advisors.
20 Most Drug Infested Cities in the U.S.
The 20 most drug infested cities in the US are a reminder that drugs are indeed a major problem in the US.
Is Alkermes Plc (ALKS) Going To Burn These Hedge Funds ?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset...
5 Opioid Treatment Stocks
The five opioid treatment stocks are among several companies that have taken their own approach to the growing opioid addiction market in the US, which also happens to be the ...
Netflix, Inc. (NFLX), General Electric Company (GE): Mott Capital Management’s Top Winners and Losers of 2017
Mott Capital Management is a thematic growth fund that was founded in 2014 by Michael J. Kramer. Mr.
10 Biggest Antidepressant Drug Companies In 2017
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide...
Here’s What Mott Capital Management Thinks About Netflix, Alkermes, Vodafone & More
Mott Capital Management was founded in 2014 by Michael J. Kramer.
Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More
Michael Kramer's Mott Capital just released its Q4 letter to investors, which discussed the fund's trying 2016 and some of its portfolio moves during the fourth quarter of last...
Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government.
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?
Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald.
Reynolds American, Inc. (RAI), MGP Ingredients Inc (MGPI), and More: Here’s What Analysts Had To Say About These Stocks in the Spotlight
Given that analysts can often affect short term sentiment, we at Insider Monkey have put together a list of recent Wall Street analyst commentary concerning five stocks, Reynolds...
Why Traders Are Buzzing About Qualcomm, NXP, Alkermes, Cerecor, and More
Although the earnings reports from various tech giants have grabbed most of the attention today, several other companies are also trending.
Hedge Funds Regret Buying These Stocks in Q4
Hedge funds are able to charge their clients high fees because of their ability to deliver superior returns and outperform benchmarks.
Why These 5 Stocks Are Plummeting Today
The markets have finally managed to catch a break today, as all major stock indexes have registered gains of more than 1.3%.
Woodford Investment Management Has A Lot Riding On These 5 Stocks
Woodford Investment Management recently filed its Form 13F with the U.S. Securities and Exchange Commission (SEC) for the reporting period of September 30.
These Two Stocks Are in the Spotlights and Hedge Funds Suggest One of Them is a Buy
Alkermes Plc (NASDAQ:ALKS) and Apollo Education Group Inc (NASDAQ:APOL) are in the news after the FDA approved Alkermes Plc's ARISTADA for the treatment of schizophrenia while...
Hedge Fund Resource Center
